 RESEARCH TRIANGLE PARK, N.C., Nov. 18, 2020 GLOBE NEWSWIRE -- G1 Therapeutics, Inc. Nasdaq: GTHX, a clinical-stage oncology company, today announced that final overall survival OS data from its randomized Phase 2 trial of trilaciclib in metastatic triple-negative breast cancer mTNBC were consistent with preliminary findings announced last year, and showed that trilaciclib significantly improved median OS for patients treated with trilaciclib in combination with a chemotherapy regimen of gemcitabinecarboplatin. These data will be presented in a Spotlight Poster Session at the 2020 San Antonio Breast Cancer Symposium SABCS on Wednesday, December 9. Trilaciclib is a first-in-class investigational therapy designed to improve outcomes for people with cancer treated with chemotherapy. 